Discover open access scientific publications

Search, annotate, share and cite publications

Publications by Cynthia D. Hanson

Safety and Pharmacokinetics of Amprenavir (141W94), a Human Immunodeficiency Virus (HIV) Type 1 Protease Inhibitor, Following Oral Administration of Single Doses to HIV-Infected Adults

Antimicrobial Agents and Chemotherapy

Infectious Diseases

Pharmacology

1999

English

Related publications

Safety and Pharmacokinetics of Abacavir (1592U89) Following Oral Administration of Escalating Single Doses in Human Immunodeficiency Virus Type 1-Infected Adults

Antimicrobial Agents and Chemotherapy

Infectious Diseases

Pharmacology

1999

English

Polymorphism of the Human Immunodeficiency Virus Type 1 (HIV-1) Protease Gene and Response of HIV-1-Infected Patients to a Protease Inhibitor

Journal of Clinical Microbiology

Microbiology

1999

English

Single-Dose Pharmacokinetics of Amprenavir, a Human Immunodeficiency Virus Type 1 Protease Inhibitor, in Subjects With Normal or Impaired Hepatic Function

Antimicrobial Agents and Chemotherapy

Infectious Diseases

Pharmacology

2000

English

Intracellular Expression of Human Immunodeficiency Virus Type 1 (HIV-1) Protease Variants Inhibits Replication of Wild-Type and Protease Inhibitor-Resistant HIV-1 Strains in Human T-Cell Lines.

English

Crystal Structure of Human Immunodeficiency Virus (HIV) Type 2 Protease in Complex With a Reduced Amide Inhibitor and Comparison With HIV-1 Protease Structures.

Proceedings of the National Academy of Sciences of the United States of America

Multidisciplinary

1993

English

Interactions of Single and Combined Human Immunodeficiency Virus Type 1 (HIV-1) DNA Vaccines

Virology

2001

English

Activities of the Human Immunodeficiency Virus Type 1 (HIV-1) Protease Inhibitor Nelfinavir Mesylate in Combination With Reverse Transcriptase and Protease Inhibitors Against Acute HIV-1 Infection in Vitro.

Antimicrobial Agents and Chemotherapy

Infectious Diseases

Pharmacology

1997

English

Defining the Level of Human Immunodeficiency Virus Type 1 (HIV-1) Protease Activity Required for HIV-1 Particle Maturation and Infectivity.

English

Mutation Patterns and Structural Correlates in Human Immunodeficiency Virus Type 1 Protease Following Different Protease Inhibitor Treatments

English

Amanote Research

Discover open access scientific publications

Search, annotate, share and cite publications

Publications by Cynthia D. Hanson

Safety and Pharmacokinetics of Amprenavir (141W94), a Human Immunodeficiency Virus (HIV) Type 1 Protease Inhibitor, Following Oral Administration of Single Doses to HIV-Infected Adults

Related publications

Safety and Pharmacokinetics of Abacavir (1592U89) Following Oral Administration of Escalating Single Doses in Human Immunodeficiency Virus Type 1-Infected Adults

Polymorphism of the Human Immunodeficiency Virus Type 1 (HIV-1) Protease Gene and Response of HIV-1-Infected Patients to a Protease Inhibitor

Single-Dose Pharmacokinetics of Amprenavir, a Human Immunodeficiency Virus Type 1 Protease Inhibitor, in Subjects With Normal or Impaired Hepatic Function

Intracellular Expression of Human Immunodeficiency Virus Type 1 (HIV-1) Protease Variants Inhibits Replication of Wild-Type and Protease Inhibitor-Resistant HIV-1 Strains in Human T-Cell Lines.

Crystal Structure of Human Immunodeficiency Virus (HIV) Type 2 Protease in Complex With a Reduced Amide Inhibitor and Comparison With HIV-1 Protease Structures.

Interactions of Single and Combined Human Immunodeficiency Virus Type 1 (HIV-1) DNA Vaccines

Activities of the Human Immunodeficiency Virus Type 1 (HIV-1) Protease Inhibitor Nelfinavir Mesylate in Combination With Reverse Transcriptase and Protease Inhibitors Against Acute HIV-1 Infection in Vitro.

Defining the Level of Human Immunodeficiency Virus Type 1 (HIV-1) Protease Activity Required for HIV-1 Particle Maturation and Infectivity.

Mutation Patterns and Structural Correlates in Human Immunodeficiency Virus Type 1 Protease Following Different Protease Inhibitor Treatments